LYNX1 expression was temporally reduced in pluripotent FXS NPCs and the reduction was no longer visible at day 30 in ESC-derived NPCs (Peteri et al., 2021), suggesting that LYNX1 is involved in altered control of molecular signaling that regulates fate of FXS NPCs. The gene discussed is LYNX1; the disease is fragile X syndrome.